4.8 Article

Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 128, 期 4, 页码 1371-1383

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI96153

关键词

-

资金

  1. Susan G. Komen
  2. National Cancer Institute (NCI), NIH, Breast Specialized Programs of Research Excellence (SPOREs) [P50-CA58223, RO1-CA195754-01, RO1-CA148761, K23-157728]
  3. Breast Cancer Research Foundation [16-023, 17-124]
  4. NCI [T32 2-T32-CA071341-16, T32 GM008719, F30-CA200345]
  5. NATIONAL CANCER INSTITUTE [P30CA016086, T32CA071341, P50CA058223, P30CA016058, K23CA157728, R01CA195754, R01CA148761, F30CA200345] Funding Source: NIH RePORTER
  6. NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER
  7. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008719] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Breast cancer metastasis remains a clinical challenge, even within a single patient across multiple sites of the disease. Genome-wide comparisons of both the DNA and gene expression of primary tumors and metastases in multiple patients could help elucidate the underlying mechanisms that cause breast cancer metastasis. To address this issue, we performed DNA exome and RNA sequencing of matched primary tumors and multiple metastases from 16 patients, totaling 83 distinct specimens. We identified tumor-specific drivers by integrating known protein-protein network information with RNA expression and somatic DNA alterations and found that genetic drivers were predominantly established in the primary tumor and maintained through metastatic spreading. In addition, our analyses revealed that most genetic drivers were DNA copy number changes, the TP53 mutation was a recurrent founding mutation regardless of subtype, and that multiclonal seeding of metastases was frequent and occurred in multiple subtypes. Genetic drivers unique to metastasis were identified as somatic mutations in the estrogen and androgen receptor genes. These results highlight the complexity of metastatic spreading, be it monoclonal or multiclonal, and suggest that most metastatic drivers are established in the primary tumor, despite the substantial heterogeneity seen in the metastases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study

Amber N. Hurson, Mustapha Abubakar, Alina M. Hamilton, Kathleen Conway, Katherine A. Hoadley, Michael Love, Andrew F. Olshan, Charles M. Perou, Montserrat Garcia-Closas, Melissa A. Troester

Summary: This study identified breast cancer risk factors associated with RNA-based TP53 and ER, providing a new etiologic schema of interest in breast cancer prevention research.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)

Article Oncology

Gene-Level Germline Contributions to Clinical Risk o f Recurrence Scores in Black and White Patients with Breast Cancer

Achal Patel, Montserrat Garcia-Closas, Andrew F. Olshan, Charles M. Perou, Melissa A. Troester, Michael Love, Arjun Bhattacharya

Summary: This study identifies race-specific genetic associations with breast cancer risk of recurrence scores and suggests mediation of these associations by PAM50 subtype and expression, with implications for clinical interpretation of these scores.

CANCER RESEARCH (2022)

Article Oncology

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer

Jonathan H. Shepherd, Karla Ballman, Mei-Yin C. Polley, Jordan D. Campbell, Cheng Fan, Sara Selitsky, Aranzazu Fernandez-Martinez, Joel S. Parker, Katherine A. Hoadley, Zhiyuan Hu, Yan Li, Matthew G. Soloway, Patricia A. Spears, Baljit Singh, Sara M. Tolaney, George Somlo, Elisa R. Port, Cynthia Ma, Charles Kuzma, Eleftherios Mamounas, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen M. Hahn, Clifford A. Hudis, Eric P. Winer, Ann Partridge, Terry Hyslop, Lisa A. Carey, Charles M. Perou, William M. Sikov

Summary: The long-term outcomes of the CALGB 40603 trial showed that adding carboplatin or bevacizumab did not significantly improve the overall survival of patients with stage II-III triple-negative breast cancer. However, patients who achieved a pathological complete response had better long-term outcomes, and immune activation markers were associated with treatment response and improved survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

Carey K. Anders, Mark G. Woodcock, Amanda E. D. Van Swearingen, Dominic T. Moore, Maria J. Sambade, Sonia Laurie, Alexander Robeson, Oleg Kolupaev, Luz A. Cuaboy, Amy L. Garrett, Karen McKinnon, Kristen Cowens, Dante Bortone, Benjamin C. Calhoun, Alec D. Wilkinson, Lisa Carey, Trevor Jolly, Hyman Muss, Katherine Reeder-Hayes, Rebecca Kaltman, Rachel Jankowitz, Vinay Gudena, Oludamilola Olajide, Charles Perou, E. Claire Dees, Benjamin G. Vincent, Jonathan S. Serody

Summary: This study evaluated the efficacy of using a low dose of cyclophosphamide (Cy) to deplete regulatory T cells (T-regs) before initiating pembrolizumab in patients with triple negative breast cancer (TNBC). The results showed that Cy did not significantly decrease T-regs before pembrolizumab and there was a rapid recovery in T-regs after the first cycle of therapy. Baseline samples with increased B cell gene expression were associated with clinical response and immune-related toxicity (IRT).

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Oncology

The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer Patients

Alina M. Hamilton, Amber N. Hurson, Linnea T. Olsson, Andrea Walens, Joseph Nsonwu-Farley, Erin L. Kirk, Yara Abdou, Stephanie M. Downs-Canner, Jonathan S. Serody, Charles M. Perou, Benjamin C. Calhoun, Melissa A. Troester, Katherine A. Hoadley

Summary: The immune microenvironment in breast cancer is closely related to race, age, tumor subtype, and grade. Black and young women have higher immune response, which may be associated with higher recurrence risk.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)

Article Medicine, Research & Experimental

Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition

Sm N. Udden, Qian Wang, Sunil Kumar, Venkat S. Malladi, Shwu-Yuan Wu, Shuguang Wei, Bruce A. Posner, Sophie Geboers, Noelle S. Williams, Yulun Liu, Jayesh K. Sharma, Ram S. Mani, Srinivas Malladi, Karla Parra, Mia Hofstad, Ganesh Raj, Jose M. Larios, Reshma Jagsi, Max S. Wicha, Ben Ho Park, Gaorav P. Gupta, Arul M. Chinnaiyan, Cheng-Ming Chiang, Prasanna G. Alluri

Summary: High-throughput screening of FDA-approved drugs identified BET inhibitor OTX015 as a top suppressor of ESR1 mutant cell growth, showing superior efficacy compared to fulvestrant. When combined with CDK4/6 inhibitor abemaciclib, OTX015 induced more potent tumor regression than current standard-of-care treatment.

JCI INSIGHT (2022)

Article Medicine, General & Internal

Analytical Validation of NavDx, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Cancers

Alicia Gunning, Sunil Kumar, Cassin Kimmel Williams, Barry M. Berger, Stephen P. Naber, Piyush B. Gupta, Catherine Del Vecchio Fitz, Charlotte Kuperwasser

Summary: The NavDx blood test is a reliable method for detecting and monitoring HPV-driven cancers by analyzing tumor tissue modified viral-HPV DNA. It has been clinically validated and integrated into clinical practice by over 1000 healthcare providers at over 400 medical sites in the US. The test is accredited by the College of American Pathologists and the New York State Department of Health and has demonstrated high sensitivity and specificity.

DIAGNOSTICS (2023)

Article Oncology

Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence

Frederick M. Howard, James Dolezal, Sara Kochanny, Galina Khramtsova, Jasmine Vickery, Andrew Srisuwananukorn, Anna Woodard, Nan Chen, Rita Nanda, Charles M. Perou, Olufunmilayo I. Olopade, Dezheng Huo, Alexander T. Pearson

Summary: Gene expression-based recurrence assays are recommended for guiding chemotherapy in hormone receptor-positive, HER2-negative breast cancer, but their high cost and limited availability pose challenges. This study presents a deep learning model that utilizes digital histology and clinical risk factors to predict recurrence assay results and the risk of recurrence, surpassing the performance of established clinical nomograms. The model can identify patients with excellent prognoses who may not require further genomic testing.

NPJ BREAST CANCER (2023)

Article Oncology

Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Holly Tovey, Orsolya Sipos, Joel S. Parker, Katherine A. Hoadley, Jelmar Quist, Sarah Kernaghan, Lucy Kilburn, Roberto Salgado, Sherene Loi, Richard D. Kennedy, Ioannis Roxanis, Patrycja Gazinska, Sarah E. Pinder, Judith Bliss, Charles M. Perou, Syed Haider, Anita Grigoriadis, Andrew Tutt, Maggie Chon U. Cheang

Summary: This study explored the predictive ability of DNA damage response (DDR) and immune markers in the treatment response of triple-negative breast cancer. High immune features predict response to docetaxel, while high DDR signature scores predict response to carboplatin. Patients can be divided into different subgroups based on their treatment sensitivity. Caution is needed when using transcriptional signatures derived from primary tumors to guide treatment.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals TP53 Aneuploidy-driven Metabolic Reprogramming

Marni B. McClure, Yasunori Kogure, Naser Ansari-Pour, Yuki Saito, Hann-Hsiang Chao, Jonathan Shepherd, Mariko Tabata, Olufunmilayo I. Olopade, David C. Wedge, Katherine A. Hoadley, Charles M. Perou, Keisuke Kataoka

Summary: Hallmark signatures based on gene expression capture core cancer processes and have significant relationships with genetic alterations. TP53 mutation leads to diverse changes, including increased proliferation and glycolysis, similar to widespread copy-number alterations. Basal-like breast and bladder cancers demonstrate specific genetic and phenotypic changes related to squamous tumors, indicating potential therapeutic options across tumor types. These findings highlight the heterogeneity of hallmark signatures and suggest an oncogenic program induced by TP53 mutation and selected aneuploidy events.

CANCER RESEARCH COMMUNICATIONS (2023)

Article Oncology

Incorporating RNA-based Risk Scores for Genomic Instability to Predict Breast Cancer Recurrence and Immunogenicity in a Diverse Population

Alina M. Hamilton, Sarah C. Van Alsten, Xiaohua Gao, Joseph Nsonwu-Farley, Benjamin C. Calhoun, Michael I. Love, Melissa A. Troester, Katherine A. Hoadley

Summary: Markers of genomic instability, including TP53 status and HRD, are candidate biomarkers of immunogenicity and immune-mediated survival in breast cancer. This study used RNA expression to investigate the association between genomic instability and the breast cancer immune microenvironment. The results showed that genomic instability signatures were associated with immune expression and improved recurrence-free survival, highlighting the potential of genomic instability as a marker for predicting immunotherapy response.

CANCER RESEARCH COMMUNICATIONS (2023)

Article Oncology

Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study

Yifeng Shi, Linnea T. Olsson, Katherine A. Hoadley, Benjamin C. Calhoun, J. S. Marron, Joseph Geradts, Marc Niethammer, Melissa A. Troester

Summary: Approaches for rapidly identifying patients at high risk of early breast cancer recurrence are needed. Image-based methods for prescreening tumor slides stained with hematoxylin and eosin (H&E) could provide temporal and financial efficiency. Deep learning was leveraged to extract image information and train a model to identify recurrence. Our image model identified 70% of early-recurrent low-intermediate grade tumors, providing complementary information for predicting early recurrence compared to existing markers.

NPJ BREAST CANCER (2023)

Article Oncology

Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer

Ryan M. Murphy, Jason Tasoulas, Alessandro Porrello, Miranda B. Carper, Yi-Hsuan Tsai, Alisha R. Coffey, Sunil Kumar, Peter YF. Zeng, Travis P. Schrank, Bentley R. Midkiff, Stephanie Cohen, Ashley H. Salazar, Michele C. Hayward, D. Neil Hayes, Andrew Olshan, Gaorav P. Gupta, Anthony C. Nichols, Wendell G. Yarbrough, Chad V. Pecot, Antonio L. Amelio

Summary: Over 70% of oropharyngeal head and neck squamous cell carcinoma (HNSC) cases in the United States are positive for human papillomavirus (HPV). This study identified robust expression of Synaptogyrin-3 (SYNGR3) gene in immune cells of HPV(+) squamous cancers and demonstrated that codetection of SYNGR3 and p16 by immunohistochemistry (IHC) can more reliably identify the low-risk subgroup of patients that may be appropriate for deescalation treatments.

CANCER RESEARCH COMMUNICATIONS (2022)

Article Oncology

Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression

Danielle J. Fassler, Luke A. Torre-Healy, Rajarsi Gupta, Alina M. Hamilton, Soma Kobayashi, Sarah C. Van Alsten, Yuwei Zhang, Tahsin Kurc, Richard A. Moffitt, Melissa A. Troester, Katherine A. Hoadley, Joel Saltz

Summary: This study evaluated the role of tumor-infiltrating lymphocytes (TILs) in breast cancer and assessed their significance as biomarkers using computational pathology. The findings suggest that the abundance and spatial distribution of TILs are associated with clinical prognosis, and are important for predicting the risk of recurrence.

CANCERS (2022)

暂无数据